IAIrfan Ahmad

Irfan Ahmad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Research Subjects


Irfan Ahmad has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Adnan Taan Alkhafaji

    Cardiology Department, College of Medicine Al‐Ayen University Thi‐Qar Iraq

    1 shared publication
  • Ahmed Hjazi

    Department of Medical Laboratory, College of Applied Medical Sciences Prince Sattam bin Abdulaziz University Al‐Kharj Saudi Arabia

    1 shared publication
  • Ahmed Hussein Zwamel

    Medical Laboratory Technique College The Islamic University Najaf Iraq

    1 shared publication
  • Harpreet Kaur

    School of Basic & Applied Sciences Shobhit University Gangoh Uttar Pradesh India

    1 shared publication
  • Israa Hussein Mohammed

    College of nursing National University of Science and Technology Dhi‐Qar Iraq

    1 shared publication
  • Jaafaru Sani Mohammed

    Medical Analysis Department, Tishk International University, Erbil, Iraq

    1 shared publication

Latest Publications

  • LncRNA NEAT1 in the pathogenesis of liver‐related diseases

    by Raed Obaid Saleh, Adnan Taan Alkhafaji, Jaafaru Sani Mohammed, Pooja Bansal, Harpreet Kaur, Irfan Ahmad, Ahmed Hjazi, Israa Hussein Mohammed, Mohammed Abed Jawad, Ahmed Hussein Zwamel

    Nuclear paraspeckle assembly transcript 1 (NEAT1) is a long noncoding RNA (lncRNA) that is widely expressed in a variety of mammalian cell types. Altered expression levels of the lncRNA NEAT1 have been reported in liver‐related disorders including cancer, fatty liver disease, liver fibrosis, viral hepatitis, and hepatic ischemia. lncRNA NEAT1 mostly acts as a competing endogenous RNA (ceRNA) to sponge various miRNAs (miRs) to regulate different functions. In regard to hepatic cancers, the elevated expression of NEAT1 has been reported to have a relation with the proliferation, migration, angiogenesis, apoptosis, as well as epithelial‐mesenchymal transition (EMT) of cancer cells. Furthermore, NEAT1 upregulation has contributed to the pathogenesis of other liver diseases such as fibrosis. In this review, we summarize and discuss the molecular mechanisms by which NEAT1 contributes to liver‐related disorders including acute liver failure, nonalcoholic fatty liver disease (NAFLD), liver fibrosis, and liver carcinoma, providing novel insights and introducing NEAT1 as a potential therapeutic target in these diseases.